This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or ...

Just before the end of 2025, an oral version of a GLP-1 drug specifically used for weight management moved much closer to ...

Hospital trips tied to semaglutide—the active ingredient in Ozempic and Wegovy—are rare, but can be serious, a new study found Compounded versions of semaglutide could explain some of these visits, ...

Randomised trial data show GLP 1 receptor agonists are associated with increased risk of gallbladder and biliary disease, ...

Switching From Tirzepatide to semaglutide for weight loss? This article was reviewed by Lynn Marie Morski, MD, JD. Key takeaways: You can switch from tirzepatide to ...

Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.

The FDA approved a pill version of the GLP-1 receptor agonist semaglutide (Wegovy), making it the first oral GLP-1 agent ...

Dramatic drops in the risk of cancer and heart problems have been associated with weight loss drugs, but so have digestive problems and blindness There has been meteoric demand for the weight loss ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to discontinue use. Reading time 2 minutes Semaglutide’s ability to help ...

Research isn’t clear on whether semaglutide causes thyroid tumors. But people with a history of thyroid cancer may want to avoid using this diabetes and weight loss medication. Semaglutide is in a ...

Simon Spichak finished his MSc at University College Cork, where he studied the interactions between the microbes in the gut and the brain. He became interested in science communication during his ...